BNT323 + BNT327

BNT323 + BNT327 is a combination investigational therapy for advanced solid tumors, especially breast cancer. BNT323 (also known as DB-1303, trastuzumab pamirtecan) is an antibody-drug conjugate (ADC) targeting HER2, while BNT327 is a bispecific monoclonal antibody that simultaneously targets PD-L1 (for immune checkpoint inhibition) and VEGF-A (for antiangiogenesis). The rationale for this combination is to enhance anti-tumor immune responses and ADC delivery to tumor cells: BNT327 restores T-cell function and normalizes tumor vasculature, improving immune activity and potentiating penetration of ADCs like BNT323. Preclinical and clinical studies show early signs of anti-tumor activity, including partial responses and stable disease in heavily pretreated platinum-resistant ovarian cancer. They are being evaluated in hormone receptor-positive, hormone receptor-negative, HER2-positive, HER2-low, HER2-ultralow, HER2-null, and triple-negative breast cancer. Safety and dose optimization are under investigation in a global Phase 1/2 trial (NCT06827236)[3][5][1][8].

Other names

DB-1303 + BNT327trastuzumab pamirtecan + BNT327